Valuation: Genmab A/S

Market Cap 12TCr 1.76TCr 1.54TCr 1.43TCr 1.32TCr 2.47TCr 1,69100Cr 2.51TCr 17TCr 6.66TCr 83TCr 6.59TCr 6.45TCr 2,87500Cr P/E 2026 *
24.5x
P/E 2027 * 17x
Enterprise Value 13TCr 2.05TCr 1.8TCr 1.68TCr 1.54TCr 2.89TCr 1,97600Cr 2.93TCr 20TCr 7.77TCr 97TCr 7.7TCr 7.54TCr 3,35900Cr EV / Sales 2026 *
4.77x
EV / Sales 2027 * 3.83x
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
1 day-1.34%
1 week+0.51%
Current month+4.65%
1 month+9.15%
3 months+9.79%
6 months-11.81%
Current year-7.33%
1 week 1,823.5
Extreme 1823.5
1,917
1 month 1,704
Extreme 1704
1,933
Current year 1,512
Extreme 1512
2,257
1 year 1,337
Extreme 1337
2,257
3 years 1,157
Extreme 1157
2,814
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Date Insider Type Main position Quantity % Market Cap.
01/12/25 Fiscal year

Director

189 0.0003%
01/12/25 Fiscal year

Chairman

378 0.0006%
01/12/25 Fiscal year

Director

189 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-1.34%+0.51%+26.03%-29.41% 1.76TCr
+0.93%+6.97%+59.60%+68.35% 5.73TCr
-1.92%+6.03%+40.64%+83.42% 5.5TCr
-0.46%-1.29%+2.86%+428.78% 2.32TCr
-2.97%-2.35%-22.53%-16.40% 2.26TCr
-0.36%+5.73%+24.13%-6.24% 2.05TCr
-1.44%+5.67%+38.77%+504.71% 1.57TCr
-1.30%-5.02%+170.77%+291.37% 1.45TCr
-0.50%-0.98%+21.43%+180.07% 1.39TCr
+0.21%-1.62%+82.48%+158.51% 1.26TCr
Average -0.92%+0.99%+44.42%+166.32% 2.53TCr
Weighted average by Cap. -0.82%+1.91%+41.83%+134.74%

Financials

2026 *2027 *
Net sales 2.82TCr 430.15Cr 377.8Cr 351.35Cr 322.41Cr 605.78Cr 41TCr 615.12Cr 4.17TCr 1.63TCr 20TCr 1.61TCr 1.58TCr 70TCr 3.32TCr 505.24Cr 443.75Cr 412.68Cr 378.69Cr 711.53Cr 49TCr 722.5Cr 4.9TCr 1.91TCr 24TCr 1.9TCr 1.86TCr 83TCr
Net income 481.52Cr 73Cr 64Cr 60Cr 55Cr 103.27Cr 7.06TCr 104.86Cr 711.23Cr 277.87Cr 3.47TCr 275.27Cr 269.34Cr 12TCr 705.4Cr 107.42Cr 94Cr 88Cr 81Cr 151.28Cr 10TCr 153.61Cr 1.04TCr 407.07Cr 5.09TCr 403.26Cr 394.57Cr 18TCr
Net Debt 1.94TCr 295.46Cr 259.5Cr 241.33Cr 221.45Cr 416.09Cr 28TCr 422.51Cr 2.87TCr 1.12TCr 14TCr 1.11TCr 1.09TCr 48TCr 1.18TCr 179.98Cr 158.08Cr 147.01Cr 134.9Cr 253.46Cr 17TCr 257.37Cr 1.75TCr 682.01Cr 8.52TCr 675.64Cr 661.08Cr 29TCr
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,088
Date Price Change Volume
24/26/24 DKK 1,878.50 -1.34% 78,748
23/26/23 DKK 1,904.00 -0.37% 85,139
22/26/22 DKK 1,911.00 +3.16% 1,32,427
21/26/21 DKK 1,852.50 +0.30% 77,644
20/26/20 DKK 1,847.00 -1.18% 1,00,442
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
1,878.50DKK
Average target price
2,392.08DKK
Spread / Average Target
+27.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock